| Ident. | Authors (with country if any) | Title |
|---|
| 000041 (2011) |
S. Wailke [Allemagne] ; J. Herzog [Allemagne] ; K. Witt [Allemagne] ; G. Deuschl [Allemagne] ; J. Volkmann [Allemagne] | Effect of controlled‐release levodopa on the microstructure of sleep in Parkinson’s disease |
| 000080 (2010) |
Y. Winter ; M. Balzer-Geldsetzer ; A. Spottke [Allemagne] ; J. P. Reese ; E. Baum ; J. Klotsche ; J. Rieke ; A. Simonow [Allemagne] ; K. Eggert ; W. H. Oertel ; R. Dodel | Longitudinal study of the socioeconomic burden of Parkinson’s disease in Germany |
| 000096 (2010) |
H. Reichmann ; W. H. Jost [Allemagne] | Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease |
| 000107 (2010) |
P. Borghammer [Danemark] ; K. Stergaard [Danemark] ; P. Cumming [Allemagne] ; A. Gjedde [Danemark] ; A. Rodell [Danemark] ; N. Hall [Danemark] ; M. M. Chakravarty [Danemark, États-Unis] | A deformation‐based morphometry study of patients with early‐stage Parkinson’s disease |
| 000119 (2009) |
A. C. Ludolph [Allemagne] ; J. Kassubek [Allemagne] ; B. G. Landwehrmeyer [Allemagne] ; E. Mandelkow [Allemagne] ; E. Mandelkow [Allemagne] ; D. J. Burn [Royaume-Uni] ; D. Caparros-Lefebvre [France] ; K. A. Frey [États-Unis] ; J. G. De Yebenes [Espagne] ; T. Gasser [Allemagne] ; P. Heutink [Pays-Bas] ; G. Höglinger [Allemagne] ; Z. Jamrozik [Pologne] ; K. A. Jellinger [Autriche] ; A. Kazantsev [États-Unis] ; H. Kretzschmar [Allemagne] ; A. E. Lang [Canada] ; I. Litvan [États-Unis] ; J. J. Lucas [Espagne] ; P. L. Mcgeer [Canada] ; S. Melquist [États-Unis] ; W. Oertel [Allemagne] ; M. Otto [Allemagne] ; D. Paviour [Royaume-Uni] ; T. Reum [Allemagne] ; A. Saint-Raymond [Royaume-Uni] ; J. C. Steele ; M. Tolnay [Suisse] ; H. Tumani [Allemagne] ; J. C. Van Swieten [Pays-Bas] ; M. T. Vanier [France] ; J. Vonsattel [États-Unis] ; S. Wagner [Allemagne] ; Z. K. Wszolek [États-Unis] | Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options |
| 000128 (2009) |
A. H. Schapira [Royaume-Uni] ; Yves Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne] | Perspectives on recent advances in the understanding and treatment of Parkinson’s disease |
| 000145 (2009) |
H. F. Harbo [Norvège] ; J. Finsterer [Autriche] ; J. Baets [Belgique] ; C. Van Broeckhoven [Belgique] ; S. Di Donato [Italie] ; B. Fontaine [France] ; P. De Jonghe [Belgique] ; A. Lossos [Israël] ; T. Lynch [Irlande (pays)] ; C. Mariotti [Italie] ; L. Schöls [Allemagne] ; A. Spinazzola [Italie] ; Z. Szolnoki [Hongrie] ; S. J. Tabrizi [Royaume-Uni] ; C. Tallaksen [Norvège] ; M. Zeviani [Italie] ; J. Burgunder [Suisse] ; T. Gasser [Allemagne] | EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington’s disease, Parkinson’s disease and dystonias |
| 000146 (2009) |
C. G. Bachmann ; A. Zapf [Allemagne] ; E. Brunner [Allemagne] ; C. Trenkwalder | Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias |
| 000168 (2008) |
M. R. Lemke [Allemagne] | Depressive symptoms in Parkinson’s disease |
| 000169 (2008) |
J. C. Möller [Allemagne] ; K. M. Eggert [Allemagne] ; M. Unger [Allemagne] ; P. Odin [Allemagne] ; K. R. Chaudhuri [Royaume-Uni] ; W. H. Oertel [Allemagne] | Clinical risk–benefit assessment of dopamine agonists |
| 000205 (2006) |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease |
| 000206 (2006) |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease |
| 000239 (2005) |
M. Péchevis [France] ; C. E. Clarke [Royaume-Uni] ; P. Vieregge [Allemagne] ; B. Khoshnood [France] ; C. Deschaseaux-Voinet [France] ; G. Berdeaux [France] ; M. Ziegler [France] | Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study |
| 000245 (2004) |
W. Heiss [Allemagne] ; R. Hilker [Allemagne] | The sensitivity of 18‐fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease |
| 000282 (2001) |
Paul Krack [Allemagne] ; Laurent Vercueil [Allemagne] | Review of the functional surgical treatment of dystonia |
| 000302 (1999) |
H. Przuntek ; B. Conrad [Allemagne] ; J. Dichgans ; P. H. Kraus ; P. Krauseneck ; G. Pergande ; U. Rinne [Finlande] ; K. Schimrigk ; J. Schnitker ; H. P. Vogel [Allemagne] | SELEDO: a 5‐y‐ear long‐term trial on the effect of selegiline in early parkinsonian patients treated with levodopa |
| 000323 (1997) |
S. Schwalen [Allemagne] ; J. Leclaire [Allemagne] ; M. Rechlin [Allemagne] ; J. Jörg [Allemagne] | Sleep related breathing disturbances and nocturnal akinesia in Parkinson's disease patients: a cross section study |
| 000330 (1997) |
V. V. Myllyl [Finlande] ; M. Jackson [Royaume-Uni] ; J. P. Larsen [Norvège] ; H. Baas [Allemagne] | Efficacy and safety of tolcapone in levodopa‐treated Parkinson's disease patients with “wearing‐off” phenomenon: a multicentre, double‐blind, randomized, placebo‐controlled trial |
| 000364 (1994) |
A. Röhl [Allemagne] ; H. Friedrich [Allemagne] ; G. Ulm [Allemagne] ; P. Vieregge [Allemagne] | The relevance of clinical subtypes for disease course, family history and epidemiological variables in Parkinson's disease |
